AstraZeneca stock heads into the open after a 1.2% London gain
Published on 09/18/2026 at 03:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at 122.85 GBP on the London Stock Exchange on September 17, 2026, up 1.2% from the previous session according to London quote data. The shares outperformed the FTSE 100, which added around 1% on the same day, extending AstraZeneca's recent relative strength within the index after the latest regulatory and investment news.
September 17, 2026 in numbers
AstraZeneca PLC (ISIN GB0009895292, LSE: AZN) saw its stock trade between roughly 122.26 GBP and an intraday high of 122.94 GBP in London on September 17, 2026, before closing at 122.85 GBP, a 1.2% gain for the day per London session data from finanzen.ch. Trading took place against a firm broader backdrop, with the FTSE 100 around 10,765 points as AstraZeneca's move modestly outpaced the benchmark.
As Reuters reported on September 17, 2026, the company's breast cancer treatment Enhertu, developed with Daiichi Sankyo, was approved for use in England's state-run National Health Service, expanding access beyond Scotland, where it was already available. The positive reimbursement decision removed a long-running overhang around pricing and access and was highlighted by several market commentaries as a key driver for AstraZeneca's stock advance that day. In addition, Reuters noted that AstraZeneca rose around 1% after unveiling an investment of nearly 200 million yuan to upgrade its production and supply base in Wuxi, China, giving investors another concrete growth signal.
Today’s catalysts for AstraZeneca
There was no new earnings release scheduled for AstraZeneca today based on recent coverage, but investors are likely to continue digesting the implications of the Enhertu NHS approval for the company's oncology franchise and pricing power in the U.K. market, as described by STAT. Broader market developments, including ongoing reactions to the recent U.S. interest rate move that lifted global equities and the FTSE 100, as reported by The Irish Times, may also frame sentiment toward AstraZeneca stock heading into today's session, given its role as a large-cap healthcare constituent of the index.
